German Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.
European life sciences investors LSP has closed a new fund to fight dementia at €50m.
French Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
Immuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round.
Following a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2.
Italian Angelini Pharma and Swiss CNS disease specialist Arvelle Therapeutics have entered into a definitive merger agreement.
University of Birmingham researchers have invented a COVID-19 RNA test that reduces testing time from 30 minutes to under five, and delivers accurate results.
Dear readers,
We wish all visitors to our news page a peaceful and healthy New Year and a successful start to the New Year. Stay healthy! We will be back with the latest news from 4 January.
Best regards
Your editorial team of European Biotechnology Magazine
Following a rapid FDA approval, the European drug authority EMA has recommended to conditionally approve BioNTechs mRNA vaccine BNT162b2 in the EU.
Only two and a half months after its launch, the EU bioecocomy venture capital fund ECBF has doubled the volume of its first closing.